Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). CONCLUSIONS: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [14]
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 2
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
Cited by
Items 501–600 of 1,025
Gianniou, C., Dirani, A., Jang, L., & Mantel, I. (2015) · Retina · doi:10.1097/iae.0000000000000465 · Cited by 81
“Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment, the current gold-standard treatment for nAMD, has been shown to improve and maintain the average bestcorrected visual acuity (BCVA) on the basis of monthly intravitreal reinjections.(1,2) The effect of VEGF suppression consists of both stoppin…”
BackgroundResultLoyet, K. M., DeForge, L. E., Katschke, K. J., Diehl, L., Graham, R. R., Pao, L., Sturgeon, L., Lewin-Koh, S.-C., Hollyfield, J. G., & van Lookeren Campagne, M. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9587 · Cited by 80
Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection
Artunay, Ö., Yuzbasioglu, E., Rasier, R., Şengül, E. A., & Bahçecıoğlu, H. (2009) · Eye · doi:10.1038/eye.2009.7 · Cited by 81
Tabandeh, H., Boscia, F., Sborgia, A., Ciracì, L., Dayani, P. N., Mariotti, C., Furino, C., & Flynn, H. W. (2013) · Retina · doi:10.1097/iae.0000000000000008 · Cited by 84
Current therapeutic developments in atrophic age-related macular degeneration
Hanus, J., Zhao, F., & Wang, S. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306972 · Cited by 90
Drug delivery devices for retinal diseases
Kaji, H., Nagai, N., Nishizawa, M., & Abe, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.002 · Cited by 85
Wang, F., Yu, S., Liu, K., Chen, F.-E., Song, Z., Zhang, X., Xu, X., & Sun, X. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.083 · Cited by 80
SHORT-TERM EFFICACY AND SAFETY OF INTRAVITREAL RANIBIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION
da Silva, R. M., Ruiz‐Moreno, J. M., Nascimento, J., Carneiro, Â. M., Rosa, P. C., BARBOSA, A., Carvalheira, F., de Abreu, J. R. F., & Cunha-Vaz, J. G. (2008) · Retina · doi:10.1097/iae.0b013e31817eda41 · Cited by 80
Takahashi, K. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.27 · Cited by 80
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0947-4 · Cited by 83
Blick, S. K. A., Keating, G. M., & Wagstaff, A. J. (2007) · Drugs · doi:10.2165/00003495-200767080-00007 · Cited by 81
Hutton, D. W., Newman-Casey, P. A., Tavag, M., Zacks, D. N., & Stein, J. D. (2014) · Health Affairs · doi:10.1377/hlthaff.2013.0832 · Cited by 79
DeCroos, F. C., Reed, D. C., Adam, M. K., Salz, D. A., Gupta, O. P., Ho, A. C., & Regillo, C. D. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.06.002 · Cited by 88
Okada, M., Kandasamy, R., Chong, E. W. T., McGuiness, M. B., & Guymer, R. H. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.05.026 · Cited by 82
Kaiser, P. K. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.12.057 · Cited by 80
Self-citationThe case for oxygen-ozonetherapy
Bocci, V. A. (2007) · British Journal of Biomedical Science · doi:10.1080/09674845.2007.11732755 · Cited by 91
Alexander, S. L., Linde‐Zwirble, W. T., Werther, W., Depperschmidt, E. E., Wilson, L., Palanki, R., Saroj, N., Butterworth, S. L., & Ianchulev, T. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.017 · Cited by 81
Traine, P. G., Pfister, I. B., Zandi, S., Spindler, J., & Garweg, J. G. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.01.018 · Cited by 80
Muether, P. S., Hermann, M. M., Koch, K. R., & Fauser, S. (2010) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1520-9 · Cited by 79
“The drug accreditation trials for ranibizumab utilized a fixed monthly injection regimen once AMD-associated choroidal neovascularization (CNV) had been diagnosed [ 1 , 3]. However, the European Summary of Product Characteristics suggests a loading-phase with three monthly injections, followed by a visual acuity (VA)-…”
MethodEconomic Considerations of Macular Edema Therapies
Smiddy, W. E. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.034 · Cited by 78
“Periocular therapies have been evaluated with limited or no visual efficacy,(4,5) but the advent of intravitreal therapies has induced a paradigm shift.(6,7) Mechanisms of retinal”
Emerson, M., & Lauer, A. K. (2007) · BioDrugs · doi:10.2165/00063030-200721040-00005 · Cited by 78
Ye, F., Kaneko, H., Hayashi, Y., Takayama, K., Hwang, S.-J., Nishizawa, Y., Kimoto, R., Nagasaka, Y., Tsunekawa, T., Matsuura, T., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.02.027 · Cited by 82
Shienbaum, G., Gupta, O. P., Fecarotta, C., Patel, A. H., Kaiser, R. S., & Regillo, C. D. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.011 · Cited by 77
“Ranibizumab has proven to be the first herapy for choroidal neovascularization (CNV) secondary to eovascular AMD to result in a significant improvement in isual acuity.(1,2) Intravitreal bevacizumab currently is used as an off-label treatment for neovascular AMD, having been shown to be relatively safe and effective i…”
BackgroundSchmucker, C. M., Loke, Y. K., Ehlken, C., Agostini, H. T., Hansen, L. L., Antes, G., & Lelgemann, M. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.178574 · Cited by 87
“Two of these studies showed that approximately 95% of the patients treated with monthly ranibizumab injections lost fewer than 15 letters in 12 months, compared to 64% of patients receiving photodynamic therapy (PDT)”
ResultBailey, S. T., Thaware, O. C., Wang, J., Hagag, A. M., Zhang, X., Flaxel, C. J., Lauer, A. K., Hwang, T. S., Lin, P., Huang, D., et al. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.03.008 · Cited by 85
Regatieri, C. V., Branchini, L. A., & Duker, J. S. (2011) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20110627-05 · Cited by 77
The non-antibiotic properties of tetracyclines: Clinical potential in ophthalmic disease
Federici, T. J. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.06.013 · Cited by 79
Besirli, C. G., Chinskey, N. D., Zheng, Q.-D., & Zacks, D. N. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4439 · Cited by 78
Wong, L. J., Desai, R. U., Jain, A., Feliciano, D. M., Moshfeghi, D. M., Sanislo, S. R., & Blumenkranz, M. S. (2008) · Retina · doi:10.1097/iae.0b013e31817e100f · Cited by 77
Bashshur, Z. F., Schakal, A., Hamam, R. N., Haibi, C. P. E., Jaafar, R. F., & Noureddin, B. N. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.10.1357 · Cited by 77
Bevacizumab versus Ranibizumab for AMD
Rosenfeld, P. J. (2011) · New England Journal of Medicine · doi:10.1056/nejme1103334 · Cited by 79
Bhisitkul, R. B., Winn, B. J., Lee, O.-T., Wong, J., Pereira, D. D. S., Porco, T. C., He, X., Hahn, P., & Dunaief, J. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-1892 · Cited by 76
Martín, D. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.12.019 · Cited by 78
Daïen, V., Finger, R. P., Talks, J. S., Mitchell, P., Wong, T. Y., Sakamoto, T., Eldem, B., & Korobelnik, J. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-317434 · Cited by 80
Khanani, A. M., Callanan, D., Dreyer, R., Chen, S., Howard, J. G., Hopkins, J. J., Lin, C.-Y., Lorenz-Candlin, M., Makadia, S., Patel, S., et al. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2020.11.004 · Cited by 76
Neovascular Age-Related Macular Degeneration
Shao, J., Choudhary, M. M., & SCHACHAT, A. P. (2015) · Developments in ophthalmology · doi:10.1159/000438969 · Cited by 83
Ranibizumab for Refractory Uveitis-related Macular Edema
Acharya, N. R., Hong, K. C., & Lee, S. M. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.03.028 · Cited by 76
Incidence of Damage to the Crystalline Lens During Intravitreal Injections
Meyer, C. H., Rodrigues, E. B., Michels, S., Mennel, S., Schmidt, J. C., Helb, H. –., Hager, A., Martinazzo, M., & Farah, M. E. (2010) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2010.0045 · Cited by 77
Mokwa, N., Ristau, T., Keane, P. A., Kirchhof, B., Sadda, S. R., & Liakopoulos, S. (2013) · Journal of Ophthalmology · doi:10.1155/2013/385915 · Cited by 84
“By permitting visualisation of the choroidal and retinal microcirculation and providing detailed information about the presence of pathological vessels as well as the integrity of the blood retinal barrier, fluorescein angiography (FA) had become a central tool for detecting and classifyingCNVaswell as CNVactivity in…”
BackgroundEpimacular Brachytherapy for Neovascular Age-related Macular Degeneration
Dugel, P. U., Bebchuk, J. D., Nau, J. A., Reichel, E., Singer, M. A., Barak, A., Binder, S., & Jackson, T. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.07.068 · Cited by 76
Strand and Cell Type-specific Function of microRNA-126 in Angiogenesis
Zhou, Q., Anderson, C. A., Hanus, J., Zhao, F., Ma, J., Yoshimura, A., & Wang, S. (2016) · Molecular Therapy · doi:10.1038/mt.2016.108 · Cited by 79
Wehrli, S., Tawse, K. L., Levin, M. H., Zaidi, A. M., Pistilli, M., & Brucker, A. J. (2012) · Retina · doi:10.1097/iae.0b013e31823f0c95 · Cited by 76
“Other retrospective studies have reported cases of delayed OHT after intravitreal injections of ranibizumab and/or bevacizumab for exudative AMD.”
ResultInfluentialINTRAVITREAL RANIBIZUMAB VERSUS BEVACIZUMAB FOR TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION
Iacono, P., Parodi, M. B., Papayannis, A., Kontadakis, S., Sheth, S., Cascavilla, M. L., & Bandello, F. M. (2012) · Retina · doi:10.1097/iae.0b013e31826956b7 · Cited by 75
“From large, well-designed, randomized, and controlled clinical trials, it has been established that treatment with antiangiogenic drugs, particularly anti–vascular endothelial growth factor (anti-VEGF) drugs, is able to block the progression of CNV associated with age-related macular degeneration and prevents the corr…”
BackgroundSustained delivery of a HIF-1 antagonist for ocular neovascularization
Iwase, T., Fu, J., Yoshida, T., Muramatsu, D., Miki, A., Hashida, N., Lu, L., Oveson, B., Lima e Silva, R., Seidel, C., et al. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.008 · Cited by 75
“Introduction Angiogenesis plays an important role in several disease processes including tumor growth, rheumatoid arthritis, corneal transplant rejection, neovascular age-related macular degeneration (NVAMD), and proliferative diabetic retinopathy (PDR).”
BackgroundInfluentialKuwayama, S., Ayatsuka, Y., Yanagisono, D., Uta, T., Usui, H., Kato, A., Takase, N., Ogura, Y., & Yasukawa, T. (2019) · Journal of Ophthalmology · doi:10.1155/2019/6319581 · Cited by 83
Khanani, A. M., Brown, D. M., Jaffe, G. J., Wykoff, C. C., Adiguzel, E., Wong, R., Meng, X., & Heier, J. S. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.04.028 · Cited by 76
Self-citationCsaky, K. G., Dugel, P. U., Pierce, A. J., Fries, M. A., Kelly, D. S., Danis, R. P., Wurzelmann, J. I., Xu, C., Hossain, M. S., & Trivedi, T. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.09.036 · Cited by 77
Infectious and Noninfectious Endophthalmitis After Intravitreal Bevacizumab
Jonas, J. B., Spandau, U. H., Rensch, F., von Baltz, S., & Schlichtenbrede, F. C. (2007) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.0146 · Cited by 75
Mantel, I., Niderprim, S.-A., Gianniou, C., Deli, A., & Ambresin, A. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304556 · Cited by 77
Bressler, S. B., Almukhtar, T., Bhorade, A. M., Bressler, N. M., Glassman, A. R., Huang, S. S., Jampol, L. M., Kim, J. E., & Melia, M. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.186 · Cited by 77
Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections
Sharma, S., Johnson, D. E., Abouammoh, M. A., Hollands, S., & Brissette, A. R. (2012) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2012.03.026 · Cited by 80
Regillo, C. D., BUSBEE, B. G., Ho, A. C., Ding, B., & Hašková, Z. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.07.034 · Cited by 75
Zarbin, M., Sugino, I., & Townes-Anderson, E. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0282 · Cited by 76
Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
Hang, A., Feldman, S., Amin, A., Ochoa, J. R., & Park, S. S. (2023) · Pharmaceuticals · doi:10.3390/ph16081140 · Cited by 85
“05 mL AMD, DR, DME, ME due to RVO, myopic choroidal neovascularization AMD: MARINA [81], ANCHOR [82] DME: RISE, RIDE [48] RVO: BRAVO, CRUISE [51] 2006”
BackgroundInfluentialKataoka, K., Itagaki, K., Hashiya, N., Wakugawa, S., Tanaka, K., Nakayama, M., Yamamoto, A., Mukai, R., Honjo, J., Maruko, I., et al. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06222-x · Cited by 78
Whitmire, W., Al-Gayyar, M. M. H., Abdelsaid, M. A., Yousufzai, B., & El‐Remessy, A. B. (2011) · PubMed Central · Cited by 90
Fung, A. E., Palanki, R., Bakri, S. J., Depperschmidt, E. E., & Gibson, A. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.09.014 · Cited by 77
Brown, D. M., Tuomi, L., & Shapiro, H. (2013) · Retina · doi:10.1097/iae.0b013e318263cedf · Cited by 74
Self-citationLichtlen, P., Lam, T. T., Nork, T. M., Streit, T., & Urech, D. M. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4890 · Cited by 73
Rapid Expansion of Intravitreal Drug Injection Procedures, 2000 to 2008
Bell, C. M. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.19 · Cited by 75
Morimoto, M., Matsumoto, H., Mimura, K., & Akiyama, H. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3718-6 · Cited by 76
Callanan, D., Kunimoto, D., Maturi, R. K., Patel, S. S., Staurenghi, G., Wolf, S., Cheetham, J. K., Hohman, T. C., Kim, K., López, F. J., et al. (2018) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0062 · Cited by 73
“The proportion of patients with stable vision, defined as no loss or a <15-letter loss in BCVA from baseline, was also evaluated, as this was the primary endpoint in the registration studies for ranibizumab and aflibercept in nAMD.(4,5,17) At week 16, the proportion of patients with stable vision among those who remai…”
MethodResultSelf-citationStorey, P. P., Pancholy, M. S., Wibbelsman, T. D., Obeid, A., Su, D., Borkar, D. S., Garg, S. J., & Gupta, O. P. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.037 · Cited by 76
Matsuda, Y., Nonaka, Y., Futakawa, S., Imai, H., Akita, K., Nishihata, T., Fujiwara, M., Ali, Y., Bhisitkul, R. B., & Nakamura, Y. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.07.018 · Cited by 75
“However, there are some critical limitations: in clinical trials, 23% of eyes treated monthly with ranibizumab proceeded to vision worse than 20/200, and 20% to 40% failed to resolve macular fluid even after 2 years of therapy.(7,8) Furthermore, in the “real world” setting, patients receive intravitreal injections at…”
BackgroundEhlers, J. P., Zahid, R., Kaiser, P. K., Heier, J. S., Brown, D. M., Meng, X., Reese, J. L., Le, T. K., Lunasco, L. M., Hu, M., et al. (2021) · Ophthalmology Retina · doi:10.1016/j.oret.2021.02.012 · Cited by 74
Self-citationAnti-vascular endothelial growth factor for neovascular glaucoma
Simha, A. R., Braganza, A. D., Abraham, L. M., Samuel, P., & Lindsley, K. B. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007920.pub2 · Cited by 73
Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery
Eadie, B. D., Etminan, M., Carleton, B., Maberley, D., & Mikelberg, F. S. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.0059 · Cited by 74
Cheng, C., Wang, N., Wong, T. Y., Congdon, N. G., He, M., Wang, Y. X., Braithwaite, T., Casson, R. J., Cicinelli, M. V., Das, A., et al. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313308 · Cited by 80
Senabouth, A., Daniszewski, M., Lidgerwood, G. E., Liang, H. H., Hernández, D., Mirzaei, M., Keenan, S. N., Zhang, R., Han, X., Neavin, D. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31707-4 · Cited by 76
Nanoparticle–integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats
Kim, H., & Csaky, K. G. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.10.031 · Cited by 73
Subramanian, M. L., Ness, S. D., Abedi, G., Ahmed, E., Daly, M. K., Feinberg, E. B., Bhatia, S. P., Patel, P. M., Nguyen, M., & Houranieh, A. M. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.07.009 · Cited by 78
Endogenous endostatin inhibits choroidal neovascularization
Marneros, A. G., She, H., Zambarakji, H., Hashizume, H., Connolly, E., Kim, I. K., Gragoudas, E. S., Miller, J. W., & Olsen, B. R. (2007) · The FASEB Journal · doi:10.1096/fj.07-8422com · Cited by 73
Varano, M., Eter, N., Winyard, S., Wittrup-Jensen, K., Navarro, R., & Heraghty, J. (2015) · Clinical ophthalmology · doi:10.2147/opth.s92548 · Cited by 77
Liu, W., Borrell, M. A., Venerus, D. C., Mieler, W. F., & Kang‐Mieler, J. J. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.1.12 · Cited by 73
“For example, refillable rigid port delivery system (RPDS) developed by Forsight Vision4 and Genentech is in clinical trials for evaluating safety and efficacy in treatment of wet AMD.35 RPDS is an IVT implant that is the size of a grain of rice.”
BackgroundInfluentialMoussa, K., Lee, J. Y., Stinnett, S. S., & Jaffe, G. J. (2013) · Retina · doi:10.1097/iae.0b013e31828d6052 · Cited by 76
Yang, S., Li, T., Jia, H., Gao, M., Li, Y., Wan, X., Huang, Z., Li, M., Zhai, Y., Li, X., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj2177 · Cited by 76
Freund, K. B., Hoang, Q. V., Saroj, N., & Thompson, D. E. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.04.018 · Cited by 72
Querques, G., Azrya, S., Martinelli, D., Berboucha, E., Feldman, A., Pece, A., COSCAS, G. J., Soubrane, G., & Souied, E. H. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.170670 · Cited by 71
“Intravitreal ranibizumab was the first therapy for exudative AMD to show an improvement in mean visual acuity in two Phase III clinical studies.”
BackgroundSelf-citationStewart, M. (2012) · Clinical Ophthalmology · doi:10.2147/opth.s33372 · Cited by 71
Stahl, A., Stumpp, M. T., Schlegel, A., Ekawardhani, S., Lehrling, C., Martin, G., Gulotti-Georgieva, M., Villemagne, D., Forrer, P., Agostini, H. T., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9302-0 · Cited by 75
“of VEGF-A [8, 9], and pegaptanib, a PEGylated aptamer that binds the heparin-binding domain of VEGF-A [10].”
Hatz, K. B., & Prünte, C. F. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13031 · Cited by 72
“Although intravitreal anti-VEGF therapy has provided an effective treatment for nAMD (Brown et al. 2006; Rosenfeld et al. 2006), the dosing regimen that provides optimal efficacy and safety, whilst minimizing the treatment burden to the patient is still uncertain.”
BackgroundAn Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications
Dunn, E. N., Sheth, V. S., & Hariprasad, S. M. (2017) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20170130-02 · Cited by 70
Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema
Humayun, M. S., Santos, A., Altamirano, J. C., Ribeiro, R., González, R., de la Rosa, A., Shih, J., Pang, C., Jiang, F., Calvillo, P., et al. (2014) · Translational Vision Science & Technology · doi:10.1167/tvst.3.6.5 · Cited by 76
NON–FULL-THICKNESS MACULAR HOLES REASSESSED WITH SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
Michalewska, Z., Michalewski, J., Odrobina, D., & Nawrocki, J. (2011) · Retina · doi:10.1097/iae.0b013e318227a9ef · Cited by 70
Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions
Aronow, M. E., & Chew, E. Y. (2014) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000046 · Cited by 70
“Lower zinc dose and elimination of b-carotene Lowering zinc dose (from 80 to 25 mg) and eliminating b-carotene had no statistically significant effect on progression to advanced AMD.”
InfluentialMonthly Ranibizumab for Nonproliferative Macular Telangiectasia Type 2: A 12-Month Prospective Study
Issa, P. C., Finger, R. P., Kruse, K., Baumüller, S., Scholl, H. P. N., & Holz, F. G. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.11.019 · Cited by 71
Doukas, J., Mahesh, S. P., Umeda, N., Kachi, S., Akiyama, H., Yokoi, K., Cao, J., Chen, Z., Dellamary, L. A., Tam, B. Y. Y., et al. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21426 · Cited by 70
“Intraocular injections every month for a year of ranibizumab, an antibody fragment that binds all isoforms of VEGF-A, eliminated severe vision loss in 95% of patients and significantly improved vision in 33–44% of patients (Brown et al., 2006; Rosenfeld et al., 2006) The results with ranibizumab are impressive, becaus…”
BackgroundProgress in defining the molecular biology of age related macular degeneration
Lotery, A. J., & Trump, D. (2007) · Human Genetics · doi:10.1007/s00439-007-0406-3 · Cited by 75
“…the phase III ANCHOR trial of patients with predominantly classic subfoveal CNV secondary to AMD, 94% and 96% of Ranibizumab-treated patients (0.3 and 0.5 mg, respectively) lost <15 letters of visual acuity compared with 64% of photodynamic therapy-treated patients in month 12 (Brown et al. 2006).”
ResultInfluentialfor the OCEAN study group, Ziemssen, F., Feltgen, N., Holz, F., Guthoff, R., Ringwald, A., Bertelmann, T., Wiedon, A., & Korb, C. A. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0401-y · Cited by 71
Hikichi, T., Higuchi, M., Matsushita, T., Kosaka, S., Matsushita, R., Takami, K., Ohtsuka, H., & Ariga, H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.12.019 · Cited by 69
Clement, S., Chen, W., Deng, W., & Goldys, E. M. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s164967 · Cited by 72
Scott, A. W., & Bressler, S. B. (2013) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32835fefee · Cited by 71
Nangia, V., Jonas, J. B., George, R., Lingam, V., Ellwein, L., Cicinelli, M. V., Das, A., Flaxman, S. R., Keeffe, J. E., Kempen, J. H., et al. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312292 · Cited by 68
Weigert, G., Michels, S., Sacu, S., Varga, A., Prager, F., Geitzenauer, W., & Schmidt-Erfurth, U. M. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.125823 · Cited by 69
Solomon, S. D., Lindsley, K. B., Krzystolik, M. G., Vedula, S. S., & Hawkins, B. S. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.002 · Cited by 68
Antiangiogenesis therapy: an update after the first decade
Falco, S. D. (2014) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2014.29.1.1 · Cited by 78
“Macugen slowed the progression of vision loss, but did not yield clinically significant improvements in visual acuity [60].”
BackgroundThe Role of Osteopontin in Microglia Biology: Current Concepts and Future Perspectives
Rosmus, D.-D., Lange, C., Ludwig, F., Ajami, B., & Wieghofer, P. (2022) · Biomedicines · doi:10.3390/biomedicines10040840 · Cited by 67
Peng, S., Adelman, R. A., & Rizzolo, L. J. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4162 · Cited by 70
“These anti-VEGF drugs have reduced or eliminated macular edema with significant improvement of vision and have led to better long-term results.(25) Ranibizumab was approved for treatment of AMD by the U.”
Intravitreal ranibizumab (Lucentis®) for the treatment of myopic choroidal neovascularization
Konstantinidis, L., Mantel, I., Pournaras, J.-A. C., Zografos, L., & Ambresin, A. (2008) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0995-0 · Cited by 74
“Extensive, stringent, multicenter, randomized clinical trials have shown that ranibizumab provides significant VA benefit to patients with all angiographic subtypes of CNV related to AMD (i.e., minimally or predominantly classic or occult with no classic component), with a low incidence of serious ocular and non-ocula…”
BackgroundInfluentialGillies, M. C., Nguyen, V., Daïen, V., Arnold, J., Morlet, N., & Barthelmes, D. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.08.016 · Cited by 71
Metadata
- Authors
- Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S.
- Affiliations
- Houston Methodist (US)
- Cleveland Clinic (US)
- Retina Care Specialists (US)
- Ophthalmic Consultants of Boston (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1432-1444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085712747
- Cited by
- 3,522
- References
- 19
- Citations by year
- 2026: 97 · 2025: 110 · 2024: 115 · 2023: 97 · 2022: 117 · 2021: 189 · 2020: 178 · 2019: 140 · 2018: 154 · 2017: 170 · 2016: 188 · 2015: 209 · 2014: 218 · 2013: 247 · 2012: 257
- FWCI
- 161.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, verteporfin, neovascular age-related macular degeneration, anti-VEGF therapy, photodynamic therapy, intravitreal injection, visual acuity, endophthalmitis, uveitis
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Visual Acuity, Photosensitizing Agents, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.